리 증후군 치료 시장 : 질환 유형별, 약물 유형별, 연령층별, 유통 채널별, 지역별

Global Leigh Syndrome Treatment Market, By Disease Type, By Drug Type, By Age Group, By Distribution Channel, By Geography

US $ 4,500 ￦ 6,676,000

Unprintable PDF & Excel (Single User License)

PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 7,000 ￦ 10,385,000

PDF & Excel (Multi User License - Up to 7 Users)

PDF & Excel 보고서를 동일 기업 최대 7명까지 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능하며, 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

US $ 10,000 ￦ 14,837,000

PDF & Excel (Corporate User License)

PDF & Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

리 증후군 치료 세계 시장은 2025년에 2억 7,330만 달러로 추정되며, 2032년에는 4억 3,600만 달러에 달할 것으로 예상되며, 2025년부터 2032년까지 연평균 6.9%의 성장률을 보일 것으로 예상됩니다.

보고서 범위		보고서 상세
기준 연도	2024년	2025년 시장 규모	2억 7,330만 달러
실적 데이터	2020년부터 2024년까지	예측 기간	2025년부터 2032년까지
예측 기간 : 2025-2032년 CAGR	6.90	2032년 가치 예측	4억 3,600만 달러

리 증후군(Leigh's syndrome)은 리 뇌병증으로도 알려져 있으며, 보통 영아기 또는 유아기에 발병하는 희귀한 중증 신경 질환입니다. 이 질환은 정신 및 운동 능력의 점진적인 상실을 특징으로 하며, 심각한 신경학적 장애를 유발하고, 종종 2-3세 이전에 사망에 이르게 합니다. 그러나 일부 환자는 발병이 느리고 생존 기간이 길며 경미한 경과를 보이는 경우도 있습니다. 리 증후군은 유전적으로 불균일하며 다양한 유전자의 돌연변이에 의해 발생합니다.

• 미토콘드리아 DNA 돌연변이: 미토콘드리아 DNA(mtDNA)는 모계 유전(어머니로부터만 물려받음)입니다.
• 핵 DNA의 돌연변이: 보다 일반적으로 상염색체 열성으로 유전되는 핵 DNA에 존재하는 유전자의 돌연변이가 리 증후군을 유발합니다. 즉, 각 세포 내의 유전자 사본이 모두 돌연변이를 가지고 있다는 것을 의미합니다.

리 증후군의 원인이 되는 돌연변이는 일반적으로 세포 내 에너지 생산 구조인 미토콘드리아의 기능에 장애를 일으킵니다. 많은 경우, 미토콘드리아의 에너지 생성 과정의 일부인 산화적 인산화에 장애가 발생합니다. 이 장애로 인해 광범위한 에너지 부족이 발생하여 특히 뇌, 근육, 심장 등 에너지 수요가 많은 기관과 조직에 영향을 미칩니다.

시장 역학:

세계 리 증후군 치료 시장은 아급성 괴사성 뇌척수증 또는 리병이라고도 불리는 이 희귀한 신경 유전성 질환의 유병률 증가로 인해 지난 몇 년 동안 괄목할 만한 성장세를 보이고 있습니다. 리 증후군은 주로 중추신경계에 영향을 미치는 기저핵과 뇌간의 양측성 병변을 특징으로 하는 희귀 질환으로, 미토콘드리아 질환입니다. 보통 영아기나 유아기에 나타나며, 발달 지연이나 퇴행, 운동 장애, 쇠약감, 시력 및 청력 장애 등을 유발합니다. 효과적인 치료법 개발을 위한 연구 활동의 활성화와 이 심각한 질병에 대한 인식이 높아지면서 시장 성장을 촉진하고 있습니다.

그러나 높은 치료비, 승인된 치료 옵션의 부족, 질병 특이적 치료의 부족, 희귀 유전성 질환의 진단의 어려움 등의 요인으로 인해 시장 성장이 제한될 수 있습니다. 시장 관계자들에게는 효능을 개선한 신약 개발, 유전자 치료 및 미토콘드리아 이식 연구에 집중, 임상 연구자와의 협력, 신흥국 시장에서의 개발 등 다양한 비즈니스 기회가 있습니다.

본 조사의 주요 특징

• 세계의 리 증후군 치료 시장에 대해 조사 분석했으며, 2024년을 기준 연도로 하여 예측 기간(2025-2032년)의 시장 규모와 연평균 성장률(CAGR)에 대해 조사 분석하여 전해드립니다.
• 또한, 다양한 부문에 걸친 잠재적인 수익 성장 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
• 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 주요 인사이트를 제공합니다.
• 이 보고서는 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 성과, 전략 등의 매개 변수를 기반으로 세계 리 증후군 치료 시장의 주요 기업 프로파일을 제공합니다.
• 본 조사 대상 주요 기업으로는 Abliva AB, PTC Therapeutics, VAKS Pharma, MITOCH, Medley Pharmaceuticals Ltd, Khondrion BV, OMEICOS THERAPEUTICS GMBH. 일본 스미토모제약, Taysha GTx, PicnicHealth(AllStripes), Takeda Pharmaceuticals, Biogen, Ionis Pharmaceuticals, Inc. LIMITED.
• 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형화, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
• 세계 리 증후군 치료 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 다양한 이해관계자를 대상으로 합니다.
• 이해관계자들은 세계 리 증후군 치료 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.

목차:

제1장 조사 목적과 가정

• 조사 목적
• 가정
• 약어

제2장 시장 전망

• 보고서 설명
  • 시장 정의와 범위
• 주요 요약
• Coherent Opportunity Map(COM)

제3장 시장 역학, 규제, 동향 분석

• 시장 역학
• 영향 분석
• 주요 하이라이트
• 규제 시나리오
• 제품 승인
• PEST 분석
• PORTER의 분석
• 인수합병 시나리오
• 주요 시장 기업에 의한 전략적 인사이트

제4장 세계의 리 증후군 치료 시장 - 코로나바이러스(COVID-19) 팬데믹의 영향

• COVID-19 역학
• 공급측과 수요측 분석
• 경제에 대한 영향

제5장 리 증후군 치료 시장(질환별, 2020-2032년)

• 미토콘드리아 복합체 I 결핍증
• 미토콘드리아 복합체 III 결핍증
• 미토콘드리아 복합체 IV 결핍증
• LSAD
• 기타

제6장 리 증후군 치료 시장(약제별, 2020-2032년)

• 비타민 보충제
• 항산화물질
• 칸나비디올
• 항경련제
• 기타

제7장 리 증후군 치료 세계 시장, 투여 경로별, 2020-2032년

• 경구
• 주사제
• 토픽
• 기타

제8장 세계의 리 증후군 치료 시장, 연령 그룹별, 2020-2032년

• 유아
• 청소년과 성인

제9장 리 증후군 치료 세계 시장, 유통 채널별, 2020-2032년

• 병원 약국
• 소매 약국
• 온라인 약국

제10장 리 증후군 치료 시장(지역별, 2020-2032년)

• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동
• 아프리카

제11장 경쟁 구도

• Abliva AB
• PTC Therapeutics
• VAKS Pharma
• MITOCH
• Medley Pharmaceuticals Ltd.
• Khondrion BV
• OMEICOS THERAPEUTICS GMBH.
• Edison Pharmaceuticals, Inc.
• Dainippon Sumitomo Pharma Co. Ltd.
• Taysha GTx
• PicnicHealth(AllStripes)
• Takeda Pharmaceutical Company
• Biogen
• Ionis Pharmaceuticals, Inc.
• Sarepta Therapeutics, Inc.
• MECOSON LABS PRIVATE LIMITED

제12장 섹션

• 조사 방법
• 출판사 소개

ksm

영문 목차

영문목차

Global Leigh Syndrome Treatment Market is estimated to be valued at USD 273.3 Mn in 2025 and is expected to reach USD 436.0 Mn by 2032, growing at a compound annual growth rate (CAGR) of 6.9% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 273.3 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	6.90%	2032 Value Projection:	USD 436.0 Mn

Leigh syndrome, also known as Leigh disease, is a rare, severe neurological disorder that typically becomes apparent in infancy or early childhood. It is characterized by progressive loss of mental and movement abilities, leading to severe neurological disability and often death by two to three years of age. However, some affected individuals may have a milder course of the disease with later onset and longer survival. Leigh syndrome is genetically heterogeneous, meaning it can be caused by mutations in various genes, and it can be inherited in several different ways, depending on the gene involved:

• Mitochondrial DNA Mutations: Some cases of Leigh syndrome are caused by mutations in genes found within mitochondrial DNA (mtDNA), which is inherited maternally (only passed down from mothers)
• Nuclear DNA Mutations: More commonly, the mutations associated with Leigh syndrome are in genes located on nuclear DNA, which is inherited in an autosomal recessive pattern. This means that both copies of the gene in each cell have mutations.

The mutations responsible for Leigh syndrome typically impair the function of mitochondria, the energy-producing structures within cells. This often involves disruptions in oxidative phosphorylation, which is part of the mitochondrial energy generation process. The disruption results in widespread energy deficiencies, particularly affecting organs and tissues with high energy demands such as the brain, muscle, and heart.

Market Dynamics:

The global Leigh syndrome treatment market has been witnessing notable growth over the past few years owing to the rising prevalence of this rare neurological genetic disorder that is also referred to as subacute necrotizing encephalomyelopathy or Leigh disease. Leigh syndrome is a rare disorder characterized by bilateral lesions in the basal ganglia and brainstem that primarily affects the central nervous system and is a mitochondrial disease. It usually becomes evident in infancy or early childhood and can cause developmental delays or regression, movement problems, weakness, vision/hearing problems, and others. Increasing research activities to develop effective treatment options and rising awareness about this serious illness are fueling the market growth.

However, the market growth can be limited due to factors like high cost of treatment, availability of few approved treatment options, lack of disease-specific treatment, and difficulty in diagnosing this rare genetic disorder. Various opportunities for market players lie in developing novel drugs with improved efficacy, focusing on gene therapy and mitochondrial transplantation research, collaborating with clinical researchers, and expanding in emerging markets.

Key Features of the Study:

• This report provides an in-depth analysis of the global Leigh syndrome treatment market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global Leigh syndrome treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies
• The key companies covered as a part of this study include Abliva AB, PTC Therapeutics, VAKS Pharma, MITOCH, Medley Pharmaceuticals Ltd., Khondrion BV, OMEICOS THERAPEUTICS GMBH. , Edison Pharmaceuticals, Inc. , Dainippon Sumitomo Pharma Co. Ltd., Taysha GTx, PicnicHealth (AllStripes), Takeda Pharmaceutical Company , Biogen, Ionis Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., and MECOSON LABS PRIVATE LIMITED
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global Leigh syndrome treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Leigh syndrome treatment market

Detailed Segmentation:

• By Disease Type:
  • Mitochondrial Complex I Deficiency
  • Mitochondrial Complex III Deficiency
  • Mitochondrial Complex IV Deficiency
  • LSAD
  • Others
• By Disease Type:
  • Vitamin Supplements
  • Antioxidants
  • Cannabidiol
  • Anticonvulsants
  • Others (Late Phase Drugs, etc.)
• By Route of Administration:
  • Oral
  • Injectable
  • Topical
  • Others
• By Age Group:
  • Infants
  • Teenagers and Adults
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Abliva AB
  • PTC Therapeutics
  • VAKS Pharma
  • MITOCH
  • Medley Pharmaceuticals Ltd.
  • Khondrion BV
  • OMEICOS THERAPEUTICS GMBH.
  • Edison Pharmaceuticals, Inc.
  • Dainippon Sumitomo Pharma Co. Ltd.
  • Taysha GTx
  • PicnicHealth (AllStripes)
  • Takeda Pharmaceutical Company
  • Biogen
  • Ionis Pharmaceuticals, Inc.
  • Sarepta Therapeutics, Inc.
  • MECOSON LABS PRIVATE LIMITED

Table of Contents:

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Leigh Syndrome Treatment Market, By Disease Type
  • Global Leigh Syndrome Treatment Market, By Drug Type
  • Global Leigh Syndrome Treatment Market, By Route of Administration
  • Global Leigh Syndrome Treatment Market, By Age Group
  • Global Leigh Syndrome Treatment Market, By Distribution Channel
  • Global Leigh Syndrome Treatment Market, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Strategic Insights by Key Market Players

4. Global Leigh Syndrome Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Leigh Syndrome Treatment Market, By Disease Type, 2020-2032, (US$ Million)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• Mitochondrial Complex I Deficiency
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Mitochondrial Complex III Deficiency
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Mitochondrial Complex IV Deficiency
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• LSAD
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Other
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)

6. Global Leigh Syndrome Treatment Market, By Drug Type, 2020-2032, (US$ Million)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• Vitamin Supplements
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Antioxidants
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Cannabidiol
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Anticonvulsants
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)

7. Global Leigh Syndrome Treatment Market, By Route of Administration, 2020-2032, (US$ Million)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Injectable
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Topical
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)

8. Global Leigh Syndrome Treatment Market, By Age Group, 2020-2032, (US$ Million)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• Infants
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Teenagers and Adults
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)

9. Global Leigh Syndrome Treatment Market, By Distribution Channel, 2020-2032, (US$ Million)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)

10. Global Leigh Syndrome Treatment Market, By Region, 2020-2032, (US$ Million)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Million)
  • U.S.
  • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Million)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Million)
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Million)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Million)
  • GCC
  • Israel
  • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032, (US$ Million)
  • North Africa
  • Central Africa
  • South Africa

11. Competitive Landscape

• Abliva AB
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• PTC Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• VAKS Pharma
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• MITOCH
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Medley Pharmaceuticals Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Khondrion BV
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• OMEICOS THERAPEUTICS GMBH.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Edison Pharmaceuticals, Inc.
• Dainippon Sumitomo Pharma Co. Ltd.
• Taysha GTx
• PicnicHealth (AllStripes)
• Takeda Pharmaceutical Company
• Biogen
• Ionis Pharmaceuticals, Inc.
• Sarepta Therapeutics, Inc.
• MECOSON LABS PRIVATE LIMITED

12. Section

• Research Methodology
• About us

관련자료